Fazio, F. http://orcid.org/0000-0003-4187-8912
Passucci, M.
Micozzi, J.
Di Landro, F.
Fianchi, L.
Za, T.
Manieri, V. M.
Annibali, O.
Cupelli, L.
Bongarzoni, V.
Gentili, S.
De Padua, L.
Crisanti, E.
Garzia, M. G.
Rago, A.
Piciocchi, A. http://orcid.org/0000-0001-8648-885X
Mengarelli, A. http://orcid.org/0000-0002-2606-2467
Morè, S.
De Stefano, V. http://orcid.org/0000-0002-5178-5827
Bafti, M. S.
Martelli, M.
Petrucci, M. T.
Article History
Received: 9 January 2024
Revised: 28 February 2024
Accepted: 29 February 2024
First Online: 9 March 2024
Competing interests
: FF received speaker honorarium from Janssen-Cilag, Amgen, grant for advisory board from GSK and support for attending meetings and/or travel from Janssen-Cilag, BeiGene. MP declares that he has no conflict of interest. JM declares that he has no conflict of interest. FDL declares that she has no conflict of interest. LF declares that she has no conflict of interest. TZ declares that he has no conflict of interest. VM declares that she has no conflict of interest. OA received speaker honorarium from Janssen-Cilag, Amgen and Takeda. LC declares that he has no conflict of interest. VB received speaker honorarium from Janssen-Cilag, BMS, Takeda and GSK. SG declares that she has no conflict of interest. LDP received support for attending meetings and/or travel from AstraZeneca, Janssen-Cilag, Sanofi, GSK and Amgen. EC declares that she has no conflict of interest. MGG declares that she has no conflict of interest. AR declares that she has no conflict of interest. AP declares that he has no conflict of interest. AM declares that he has no conflict of interest. SM declares that she has no conflict of interest. MB declares that he has no conflict of interest. VDS received speaker honorarium and grant from advisory board from Amgen, BMS, GSK, Sanofi, Takeda. MSB declares that she has no conflict of interest. MM received speaker honorarium from Roche, Gilead, Eusapharma, Incyte, Janssen-Cilag, Beigene and grant for advisory board from Roche, Gilead, Novartis, Takeda, Eusapharma, Incyte, Janssen-Cilag and BMS. MTP received speaker honorarium from Janssen-Cilag, BMS, Amgen, Sanofi, GSK and Takeda; grant for advisory board from Janssen-Cilag, BMS, Amgen, Sanofi, GSK, Takeda, Roche and Karyopharm; support for attending meetings and/or travel from Janssen-Cilag, Celgene-BMS, Amgen, Sanofi and Takeda.